Covidien plc  

(Public, NYSE:COV)   Watch this stock  
Find more results for COV
90.85
-0.75 (-0.82%)
Sep 19 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 90.85 - 92.15
52 week 59.72 - 92.68
Open 92.15
Vol / Avg. 0.00/2.95M
Mkt cap 41.04B
P/E 27.49
Div/yield 0.36/1.59
EPS 3.30
Shares 451.76M
Beta 1.04
Inst. own 95%
Nov 6, 2014
Q4 2014 Covidien PLC Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jul 25, 2014
Q3 2014 Covidien plc Earnings Release
Jul 25, 2014
Q3 2014 Covidien PLC Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 11.38% 15.63%
Operating margin 13.62% 20.83%
EBITD margin - 28.13%
Return on average assets 6.03% 7.59%
Return on average equity 12.58% 16.16%
Employees 38,500 -
CDP Score - 70 C

Address

20 Lower Hatch Street, Dublin 2
DUBLIN,
Ireland
+353-1-4381700 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. The Company operates its businesses through three segments: Medical Devices, which includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products and other medical products; Pharmaceuticals, which includes the development, manufacture and distribution of specialty pharmaceuticals, active pharmaceutical ingredients, contrast products and radiopharmaceuticals., and Medical Supplies, which includes the development, manufacture and sale of nursing care products, medical surgical products, SharpSafety products and original equipment manufacturer (OEM) products. In August 2014, the Company acquired Reverse MedicalCorporation. In August 2014, the Company acquired Sapheon Inc.

Officers and directors

Jose E. Almeida Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Charles J. Dockendorff Chief Financial Officer, Executive Vice President
Age: 59
Bio & Compensation  - Reuters
Brian D. King President - Emerging Markets
Age: 46
Bio & Compensation  - Reuters
John H. Masterson Senior Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Michael P. Dunford Senior Vice President - Human Resources
Age: 53
Bio & Compensation  - Reuters
James C. Clemmer Senior Vice President and President - Medical Supplies Business
Age: 49
Bio & Compensation  - Reuters
Bryan C. Hanson Group President, Covidien
Age: 46
Bio & Compensation  - Reuters
Amy A. McBride-Wendell Senior Vice President - Strategy and Business Development
Age: 52
Bio & Compensation  - Reuters
Michael Sgrignari Senior Vice President - Quality and Operations
Age: 50
Bio & Compensation  - Reuters
Peter L. Wehrly Senior Vice President, Group President - Developed Markets
Age: 54
Bio & Compensation  - Reuters